zolbetuximab + capecitabine + oxaliplatin

A drug combination of **zolbetuximab** (a monoclonal antibody targeting claudin 18.2/CLDN18.2), **capecitabine** (an oral fluoropyrimidine prodrug of 5-fluorouracil), and **oxaliplatin** (a platinum-based cytotoxic compound), used as a first-line therapy for **CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma**. - **Zolbetuximab** binds to CLDN18.2 on tumor cells, activating both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), triggering immune-mediated tumor cell lysis[2][4][5]. - **Capecitabine** interferes with DNA synthesis in rapidly dividing cancer cells by acting as an antimetabolite (converted to 5-FU)[1]. - **Oxaliplatin** causes DNA crosslinking, leading to apoptosis and cell death[1]. The combination is administered intravenously (zolbetuximab, oxaliplatin) and orally (capecitabine), and has shown superiority versus chemotherapy alone in progression-free survival and overall survival in trials[3][5]. Developed by Astellas Pharma, approved in the US as Vyloy plus CAPOX chemotherapy for first-line use in eligible gastric/GEJ cancers[3][4].

Other names

zolbetuximab + CAPOXzolbetuximab + capecitabine + oxaliplatin